Progestogen therapies: Differences in clinical effects?

Trends in Endocrinology and Metabolism

Volumn 15, Issue 6, 2004, Pages 277-285

  Wiegratz, Inka ^a   Kuhl, Herbert ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORMADINONE ACETATE; CYPROTERONE ACETATE; DIENOGEST; DROSPIRENONE; DYDROGESTERONE; ESTROGEN; ETONOGESTREL; GESTAGEN; GESTODENE; GONADOTROPIN; LEVONORGESTREL; MEDROGESTONE; MEDROXYPROGESTERONE ACETATE; NOMEGESTROL ACETATE; NORETHISTERONE; NORGESTIMATE; PROGESTERONE; PROMEGESTONE; TIBOLONE; TRIMEGESTONE;

ARTERY; BONE MINERAL; BREAST CANCER; BREAST CELL; CELL PROLIFERATION; DRUG EFFECT; ENDOMETRIUM; ESTROGEN DEFICIENCY; GONADOTROPIN RELEASE; HOT FLUSH; HUMAN; ISCHEMIC HEART DISEASE; LIPID METABOLISM; LIVER METABOLISM; MOOD; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVIEW; TREATMENT INDICATION; VENOUS THROMBOEMBOLISM;

AFFECT; BONE AND BONES; BREAST; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; DRUG THERAPY, COMBINATION; ENDOMETRIUM; ESTROGENS; FEMALE; HAIR; HORMONE REPLACEMENT THERAPY; HOT FLASHES; HUMANS; PROGESTINS; SKIN;

EID: 3843146221     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tem.2004.06.006     Document Type: Review

References (88)

1. H. Kuhl Pharmacokinetics of oestrogens and progestogens Maturitas 12 1990 171 197
2. B.R. Bhavnani Pharmacology of estrogens. Basic aspects Menopause Rev. 5 2000 9 22
3. H. Kuhl Pharmacology of estradiol and estriol Menopause Rev. 5 2000 23 44
4. B.R. Bhavnani Pharmacology of conjugated equine estrogens Menopause Rev. 5 2000 45 68
5. H. Kuhl Pharmacology of progestogens. Basic aspects - progesterone derivatives Menopause Rev. 6 2001 9 16
6. H. Rozenbaum Pharmacology of progesterone and related compounds: dydrogesterone and norpregnane derivatives Menopause Rev. 6 2001 17 28
7. S. Golbs Pharmacology of nortestosterone derivatives Menopause Rev. 6 2001 29 44
8. S. Beier Toxicology of hormonal fertility-regulating agents G. Benagiano E. Diczfalusy Endocrine Mechanisms in Fertility Regulation 1983 Raven Press 261 346
9. K. Fotherby, and A.D.S. Caldwell New progestogens in oral contraception Contraception 49 1994 1 32
10. T. Ojasoo Multivariate preclinical evaluation of progestins Menopause 2 1995 97 107
11. K. Pollow Dihydrospirorenone (ZK30595): a novel synthetic progestagen - characterization of binding to different receptor proteins Contraception 46 1992 561 574
12. K. Kontula Binding of progestins to the glucocorticoid receptor. Correlation to their glucocorticoid-like effects on in vitro functions of human mononuclear leukocytes Biochem. Pharmacol. 32 1983 1511 1518
13. W. Losert Progestogens with antimineralocorticoid activity Drug Res. 35 1985 459 471
14. A. Phillips A comparison of the potencies and activities of progestogens used in contraceptives Contraception 36 1987 181 192
15. W.G.E.J. Schoonen Hormonal properties of norethisterone, 7alpha-methyl-norethisterone and their derivatives. J. Steroid Biochem Mol. Biol. 74 2000 213 222
16. O. Herkert Sex steroids used in hormonal treatment increase vascular procoagulant activity by inducing thrombin receptor (PAR-1) expression. Role of glucocorticoid receptor Circulation 104 2001 2826 2831
17. I. Klehr-Bathmann, and H. Kuhl Formation of ethinylestradiol in postmenopausal women during continuous treatment with a combination of estradiol, estriol and norethisterone acetate Maturitas 21 1995 245 250
18. W. Kuhnz In vivo conversion of norethisterone and norethisterone acetate to ethinyl estradiol in postmenopausal women Contraception 56 1997 379 385
19. I. Wiegratz Formation of 7alpha-methyl-ethinyl estradiol during treatment with tibolone Menopause 9 2002 293 295
20. M.E. de Gooyer Tibolone is not converted by human aromatase to 7α-methyl-17α-ethynylestradiol (7α-MEE): Analyses with sensitive bioassays for estrogens and androgens with LC-MSMS Steroids 68 2003 235 243
21. T. Yamamoto Aromatization of norethisterone to ethynylestradiol in human adult liver Endocrinol. Jpn. 33 1986 527 531
22. T. Yamamoto The confirmation of norethisterone aromatization in primary human hepatocytes by the vitafiber-II cell culture system Acta Obstet. Gynaecol. Jpn. 40 1988 87 89
23. Y. Osawa Norethisterone, a major ingredient of contraceptive pills, is a suicide inhibitor of estrogen biosynthesis Science 215 1982 1249 1251
24. K. Siminoski The Cushing syndrome induced by medroxyprogesterone acetate Ann. Intern. Med. 111 1989 758 760
25. J. Salvador Time dependency and reversibility of the effects of exclusive cyproterone acetate therapy on pituitary-adrenal function in hirsute women Acta Endocrinol. 110 1985 164 169
26. R. Krattenmacher Drospirenone: pharmacology and pharmacokinetics of a unique progestogen Contraception 62 2000 29 38
27. M.I. Whitehead The role and use of progestogens Obstet. Gynecol. 75 1990 59S 76S
28. D.I. Fraser The optimal dose of oral norethindrone acetate for addition to transdermal estradiol: a multicenter study Fertil. Steril. 53 1990 460 468
29. J.H. Pickar Effects of hormone replacement therapy on the endometrium and lipid parameters: a review of randomised clinical trials, 1985 to 1995 Am. J. Obstet. Gynecol. 178 1998 1087 1099
30. J.W.W. Studd The prevention and treatment of endometrial pathology in postmenopausal women receiving exogenous oestrogens N. Pasetto The Menopause and Postmenopause 1980 MTP Press 127 139
31. The Writing Group for the PEPI Trial Effects of hormone replacement therapy on endometrial histology in postmenopausal women J. Am. Med. Assoc. 275 1996 370 377
32. T. van Gorp, and P. Neven Endometrial safety of hormone replacement therapy: review of literature Maturitas 42 2002 93 104
33. S.A.A. Beresford Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women Lancet 349 1997 458 461
34. E. Weiderpass Risk of endometrial cancer following estrogen replacement with and without progestins J. Natl. Cancer Inst. 91 1991 1131 1137
35. M. Wells Effect on endometrium of long term treatment with continuous combined oestrogen-progestogen replacement therapy: follow up study BMJ 325 2002 239
36. Collaborative Group on Hormonal Factors in Breast Cancer Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer Lancet 350 1997 1047 1059
37. Writing Group for the Women's Health Initiative Investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women J. Am. Med. Assoc. 288 2002 321 333
38. S. Hulley Noncardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II) J. Am. Med. Assoc. 288 2002 58 66
39. R.T. Chlebowski Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women J. Am. Med. Assoc. 289 2003 3243 3253
40. C. Schairer Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk J. Am. Med. Assoc. 283 2000 485 491
41. R.K. Ross Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin J. Natl. Cancer Inst. 92 2000 328 332
42. T.L. Bush Hormone replacement therapy and breast cancer: a qualitative review Obstet. Gynecol. 98 2001 498 508
43. G.A. Colditz, and B. Rosner Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study Am. J. Epidemiol. 152 2000 950 964
44. C.L. Chen Hormone replacement therapy in relation to breast cancer J. Am. Med. Assoc. 287 2002 734 741
45. V. Kirsh, and N. Kreiger Estrogen and estrogen-progestin replacement therapy and risk of postmenopausal breast cancer in Canada Cancer Causes Control 13 2002 583 590
46. J.V. Porch Estrogen-progestin replacement therapy and breast cancer risk: the Women' Health Study (United States) Cancer Causes Control 13 2002 847 854
47. L.K. Weiss Hormone replacement therapy regimens and breast cancer risk Obstet. Gynecol. 100 2002 1148 1158
48. J.R. Daling Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma Cancer 95 2002 2455 2464
49. C.I. Li Relationship between long durations and different regimens of hormone therapy and risk of breast cancer J. Am. Med. Assoc. 289 2003 3254 3263
50. C. Magnusson Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy Int. J. Cancer 81 1999 339 344
51. Million Women Study Breast cancer and hormone-replacement therapy in the Million Women Study Lancet 362 2003 419 427
52. C. Stahlberg Hormone replacement therapy and risk of breast cancer: the role of progestins Acta Obstet. Gynecol. Scand. 82 2003 335 344
53. Collaborative Group on Hormonal Factors in Breast Cancer Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countires, including 50 302 women with breast cancer and 96 973 women without the disease Lancet 350 2002 187 195
54. M. Garland Menstrual cycle characteristics and history of ovulatory infertility in relation to breast cancer risk in a large cohort of US women Am. J. Epidemiol. 147 1998 636 643
55. C.S. Potten The effect of age and menstrual cycle upon proliferative activity of the normal human breast Br. J. Cancer 58 1988 163 170
56. S. Menard Proliferation of breast carcinoma during menstrual phases Lancet 352 1998 148 149
57. L.J. Hofseth Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast J. Clin. Endocrinol. Metab. 84 1999 4559 4565
58. P. Conner A comparative study of breast cell proliferation during hormone replacement therapy: effects of tibolone and continuous combined estrogen-progestogen treatment Climacteric 7 2004 50 58
59. D.F. Hargreaves Epithelial proliferation and hormone receptor status in the normal postmenopausal breast and the effects of hormone replacement therapy Br. J. Cancer 78 1998 945 949
60. J.M. Cline Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques Am. J. Obstet. Gynecol. 174 1996 93 100
61. J.M. Cline Effects of tibolone and hormone replacement therapy on the breast of cynomolgus monkeys Menopause 9 2002 422 429
62. I.H. Suparto Contrasting effects of two hormone replacement therapies on the cardiovascular and mammary gland outcomes in surgically postmenopausal monkeys Am. J. Obstet. Gynecol. 188 2003 1132 1140
63. G. Plu-Bureau Progestogen use and decreased risk of breast cancer in a cohort study of premenopausal women with benign breast disease Br. J. Cancer 70 1994 270 277
64. H. Madjar Doppler measurement of breast vascularity in women under pharmacologic treatment of benign breast disease J. Reprod. Med. 38 1993 935 940
65. T. Gordon Menopause and coronary heart disease Ann. Intern. Med. 89 1978 157 161
66. J.C.M. Witteman Increased risk of atherosclerosis in women after the menopause BMJ 298 1989 642 644
67. T.B. Clarkson The new conundrum: do estrogens have any cardiovascular benefits? Int. J. Fertil. 47 2002 61 68
68. H.N. Hodis Estrogen in the prevention of atherosclerosis Ann. Intern. Med. 135 2001 939 953
69. D.W. Losordo Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women Circulation 89 1994 1501 1510
70. D.M. Herrington Estrogen replacement and brachial artery flow-mediated vasodilation in older women Arterioscler. Thromb. Vasc. Biol. 21 2001 1955 1961
71. J.E. Manson Estrogen plus progestin and the risk of coronary heart disease N. Engl. J. Med. 349 2003 523 534
72. D. Grady Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and estrogen/progestin replacement study follow-up (HERS II) J. Am. Med. Assoc. 288 2002 49 57
73. T.B. Clarkson Benefits of exogenous oestrogen in inhibiting stress-related coronary artery atherosclerosis Br. J. Obstet. Gynaecol. 103 Suppl 13 1996 73 79
74. M.R. Adams Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis Arterioscler. Thromb. Vasc. Biol. 17 1997 217 221
75. J.K. Williams Effects of hormone replacement therapy on reactivity of atherosclerotic arteries in cynomolgus monkeys J. Am. Coll. Cardiol. 24 1994 1757 1761
76. B. Griewing Hormone replacement therapy in postmenopausal women: carotid intima-media thickness and 3-D volumetric plaque quantification Maturitas 32 1999 33 40
77. F.R. Rosendaal Oral contraceptives, hormone replacement therapy and thrombosis Thromb. Haemost. 86 2001 112 123
78. J. Miller Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the U.S. Preventive Services Task Force Ann. Intern. Med. 136 2002 680 690
79. G. Weiss Risk of venous thromboembolism with third-generation oral contraceptives: a review Am. J. Obstet. Gynecol. 180 1999 S295 S301
80. J.C.M. Meijers Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis Thromb. Haemost. 84 2000 9 14
81. H. Kuhl Effects of progestogens on haemostasis Maturitas 24 1996 1 19
82. C. Kluft Importance of levonorgestrel dose in oral contraceptives for effects on coagulation Lancet 354 1999 832 833
83. I. Schiff The effects of progestins on vasomotor flushes J. Reprod. Med. 27 1982 498 502
84. H.I. Abdalla Prevention of bone mineral loss in postmenopausal women by norethisterone Obstet. Gynecol. 66 1985 789 792
85. R.A. Moore Livial: a review of clinical studies Br. J. Obstet. Gynaecol. 106 Suppl 19 1999 1 21
86. J.C. Gallagher Effect of progestin therapy on cortical bone and trabecular bone. Comparison with oestrogen Am. J. Med. 90 1991 171 178
87. B.B. Sherwin The impact of different doses of estrogen and progestin on mood and sexual behavior in postmenopausal women J. Clin. Endocrinol. Metab. 72 1991 336 343
88. E.S. Arafat Sedative and hypnotic effects of oral administration of micronized progesterone may be mediated through its metabolites Am. J. Obstet. Gynecol. 159 1988 1203 1209